Open AccessIs Rechallenge Appropriate in Patients that Develop Immune Checkpoint Inhibitor-Associated AKI?: COMMENTARY
Author(s) -
Anushree C. Shirali
Publication year - 2022
Publication title -
kidney360
Language(s) - English
Resource type - Journals
ISSN - 2641-7650
DOI - 10.34067/kid.0005592021
Subject(s) - nivolumab , cytotoxic t cell , ipilimumab , atezolizumab , medicine , immune system , durvalumab , immunology , immune checkpoint , antigen , cancer research , pembrolizumab , immunotherapy , biology , biochemistry , in vitro
This is an Early Access article. Please select the PDF button, above, to view it.Be sure to also read the PRO: 10.34067/KID.0003962021 and CON: 10.34067/KID.0003902021